124 related articles for article (PubMed ID: 14624145)
1. Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Narce M; Poisson JP
Curr Opin Lipidol; 2003 Dec; 14(6):651-2. PubMed ID: 14624145
[No Abstract] [Full Text] [Related]
2. Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones.
Kaimal R; Song X; Yan B; King R; Deng R
J Pharmacol Exp Ther; 2009 Jul; 330(1):125-34. PubMed ID: 19369578
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.
Yajima K; Hirose H; Fujita H; Seto Y; Fujita H; Ukeda K; Miyashita K; Kawai T; Yamamoto Y; Ogawa T; Yamada T; Saruta T
Am J Physiol Endocrinol Metab; 2003 May; 284(5):E966-71. PubMed ID: 12676649
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone stimulates IGF-binding protein-1 by a PPAR gamma-independent mechanism.
Hilding A; Hall K; Skogsberg J; Ehrenborg E; Lewitt MS
Biochem Biophys Res Commun; 2003 Apr; 303(2):693-9. PubMed ID: 12659874
[TBL] [Abstract][Full Text] [Related]
5. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
Collins AR; Meehan WP; Kintscher U; Jackson S; Wakino S; Noh G; Palinski W; Hsueh WA; Law RE
Arterioscler Thromb Vasc Biol; 2001 Mar; 21(3):365-71. PubMed ID: 11231915
[TBL] [Abstract][Full Text] [Related]
6. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes.
Sugawara A; Takeuchi K; Uruno A; Ikeda Y; Arima S; Sato K; Kudo M; Taniyama Y; Ito S
Hypertens Res; 2001 May; 24(3):229-33. PubMed ID: 11409645
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.
Asakawa M; Takano H; Nagai T; Uozumi H; Hasegawa H; Kubota N; Saito T; Masuda Y; Kadowaki T; Komuro I
Circulation; 2002 Mar; 105(10):1240-6. PubMed ID: 11889020
[TBL] [Abstract][Full Text] [Related]
8. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
Camp HS; Li O; Wise SC; Hong YH; Frankowski CL; Shen X; Vanbogelen R; Leff T
Diabetes; 2000 Apr; 49(4):539-47. PubMed ID: 10871190
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma.
Park KS; Ciaraldi TP; Lindgren K; Abrams-Carter L; Mudaliar S; Nikoulina SE; Tufari SR; Veerkamp JH; Vidal-Puig A; Henry RR
J Clin Endocrinol Metab; 1998 Aug; 83(8):2830-5. PubMed ID: 9709955
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes.
Sigrist S; Bedoucha M; Boelsterli UA
Biochem Pharmacol; 2000 Jul; 60(1):67-75. PubMed ID: 10807946
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells.
Okura T; Nakamura M; Takata Y; Watanabe S; Kitami Y; Hiwada K
Eur J Pharmacol; 2000 Nov; 407(3):227-35. PubMed ID: 11068018
[TBL] [Abstract][Full Text] [Related]
12. Troglitazone and related compounds: therapeutic potential beyond diabetes.
Fujiwara T; Horikoshi H
Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
[TBL] [Abstract][Full Text] [Related]
13. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression.
Brunmair B; Gras F; Neschen S; Roden M; Wagner L; Waldhäusl W; Fürnsinn C
Diabetes; 2001 Oct; 50(10):2309-15. PubMed ID: 11574413
[TBL] [Abstract][Full Text] [Related]
14. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
15. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma.
Wang M; Wise SC; Leff T; Su TZ
Diabetes; 1999 Feb; 48(2):254-60. PubMed ID: 10334298
[TBL] [Abstract][Full Text] [Related]
16. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.
Saubermann LJ; Nakajima A; Wada K; Zhao S; Terauchi Y; Kadowaki T; Aburatani H; Matsuhashi N; Nagai R; Blumberg RS
Inflamm Bowel Dis; 2002 Sep; 8(5):330-9. PubMed ID: 12479648
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes.
Kintscher U; Goetze S; Wakino S; Kim S; Nagpal S; Chandraratna RA; Graf K; Fleck E; Hsueh WA; Law RE
Eur J Pharmacol; 2000 Aug; 401(3):259-70. PubMed ID: 10936484
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.
Fukunaga Y; Itoh H; Doi K; Tanaka T; Yamashita J; Chun TH; Inoue M; Masatsugu K; Sawada N; Saito T; Hosoda K; Kook H; Ueda M; Nakao K
Atherosclerosis; 2001 Sep; 158(1):113-9. PubMed ID: 11500181
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism.
Davies GF; Khandelwal RL; Wu L; Juurlink BH; Roesler WJ
Biochem Pharmacol; 2001 Oct; 62(8):1071-9. PubMed ID: 11597575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
